http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022256565-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c1ed5fa32b867a83462c862c520033c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_608809a6c4db18fb12c150d2c72a5166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efd6e1b7859b9cf384df1c63367efd5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae8d75daf4320e6715259e43f0f4ee33 |
| publicationDate | 2022-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022256565-A2 |
| titleOfInvention | Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system |
| abstract | The present disclosure provides single- or double-stranded therapeutic oligonucleotides (e.g., siRNAs, shRNAs, miRNAs, gRNAs, and ASOs) having a plurality of cationic binding sites that are partially or fully saturated by a plurality of divalent cations (e.g., Ba 2+ , Be 2+ , Ca 2+ , Cu 2+ , Mg 2+ , Mn 2+ , Ni 2+ , or Zn 2+ , or a combination thereof). The therapeutic oligonucleotides may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a disease. |
| priorityDate | 2021-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.